Vivecon

Jump to: navigation, search

Vivecon™ is an investigational new drug in development for the treatment of HIV infection. It is a maturation inhibitor.

Mechanism of action

Vivecon targets the gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles. By binding to the gag polyprotein, vivecon prevents its cleavage by the protease enzyme into functional subunits. Unlike the protease inhibitors, vivecon binds the gag protein, not the protease enzyme. The resulting virus particles are structurally defective and are incapable of spreading infection through the body.[1]

References

  1. Myriad Genetics Submits IND on Vivecon 6 Dec 2007. CNNmoney.com

Linked-in.jpg